These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 34731094

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF.
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [Abstract] [Full Text] [Related]

  • 3. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M.
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [Abstract] [Full Text] [Related]

  • 4. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L.
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.
    Yoshida I, Shiba T, Taniguchi H, Takahashi M, Murano T, Hiruta N, Hori Y, Bujo H, Maeno T.
    Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1483-9. PubMed ID: 25030237
    [Abstract] [Full Text] [Related]

  • 6. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG, HAWK and HARRIER Study Investigators.
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [Abstract] [Full Text] [Related]

  • 7. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
    Roald AB, Aass HC, Moe MC.
    Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J, Biarnés M, Macbeth Study Group.
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [Abstract] [Full Text] [Related]

  • 9. Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism.
    Angermann R, Rauchegger T, Nowosielski Y, Seifarth C, Egger S, Kralinger MT, Kieselbach GF, Zehetner C.
    Acta Ophthalmol; 2021 Sep; 99(6):e869-e875. PubMed ID: 33326179
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ.
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [Abstract] [Full Text] [Related]

  • 12. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Jin E, Bai Y, Luo L, Huang L, Zhu X, Ding X, Qi H, Zhao M.
    Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL.
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [Abstract] [Full Text] [Related]

  • 15. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB.
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [Abstract] [Full Text] [Related]

  • 16. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [Abstract] [Full Text] [Related]

  • 17. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
    Chronopoulos A, Huynh E, Ashurov A, Schutz JS, Jonas JB, Hattenbach LO.
    Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
    [Abstract] [Full Text] [Related]

  • 18. SAVING SIGHT IN NEOVASCULAR AMD.
    Retina; 2020 Jul; 40 Suppl 2():S1-S12. PubMed ID: 32558673
    [No Abstract] [Full Text] [Related]

  • 19. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
    Chang AA, Broadhead GK, Hong T, Joachim N, Syed A, Schlub TE, Toth L, Peto T, Zhu M.
    Ophthalmic Res; 2015 Jul; 55(2):84-90. PubMed ID: 26637166
    [Abstract] [Full Text] [Related]

  • 20. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
    de Oliveira Dias JR, Costa de Andrade G, Kniggendorf VF, Novais EA, Takahashi VKL, Maia A, Meyer C, Watanabe SES, Farah ME, Rodrigues EB.
    Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.